URINARY GM2 ACTIVATOR PROTEIN AS A MARKER OF ACUTE RENAL FAILURE OR THE RISK OF DEVELOPING ACUTE RENAL FAILURE

摘要

The invention relates to a method of determining the risk of developing acute renal failure (ARF) in an individual, or of determining an ARF, and a method of predicting the progression of an ARF, by detecting and/or quantifying the protein Ganglioside GM2 Activator Protein (GM2AP). The failure can be due to the administration of at least one nephrotoxic agent, wherein the nephrotoxic agent can be an aminoglycoside antibiotic as for example gentamicin.